Patient ID and Oncology

Selected news for the healthcare topic - Patient ID, and the healthcare topic - Oncology We have 8 shared news items for this connection to-date.

Please provide a valid email address.

Selected Headlines

Date Headline (link) Source Relevant Snippet
3/12/2021 Medical Assistant, Full Time Medical Assistant, Full Time at NHPP Gynecologic Oncology BRIGHTWATERS, NY 11718 About the JobFULL TIME MEDICAL ASSISTANT to work at gynecologic oncology office in Bay Shore area. GYN experience with PAP smears, biopsies, pelvic ... adhering to protocols such as infection control, universal protocol and patient identification Preparing specimens and completing requisitions Writing lab/ blood/ imaging orders Maintaining cleanliness, and stocking and supplying the examination rooms Sterilizing and cleaning instruments ...
2/11/2021 Adoptive Cell Therapeutics: Logistics & Lab Testing, Upcoming Webinar Hosted by Xtalks ... oncology indications. However, orchestration of these products and lab testing in clinical trials is complex and presents unique challenges to ensuring product safety and efficacy. This includes maintaining product integrity, chain of identity, chain of custody, as well as demonstration of control of the product‚Aos critical quality attributes, all on a per-patient basis.Moreover, biomarker analyses play a critical role in patient identification, pharmacokinetic (PK) assessments of the ...
2/11/2021 Adoptive Cell Therapeutics: Logistics & Lab Testing, Upcoming Webinar Hosted by Xtalks PRWeb ... patient identification, pharmacokinetic (PK) assessments of the treatment dose, characterization of pharmacodynamics (PD) and target engagement response. TORONTO (PRWEB) February 11, 2021 Adoptive cell therapies such as chimeric antigen receptor T-cells (CAR T cells) have transformed cancer therapies and hold great promise for a widening range of oncology indications. However, orchestration of these products and lab testing in clinical trials is complex and presents unique challenges to ensuring product ...
1/28/2021 Massive Bio – Your clinical trial partner ... oncology data ecosystem for improved protocol design and real-world insights.Massive Bio controls the patient enrollment value chain starting with patient identification, following with AI-based virtual pre-screening outside the site, and resolving last mile issues for clinical trial enrollment. //massivebio.com ...
12/22/2020 Bayer and Veracyte ( Nasdaq: VCYT ) today announced a new collaboration to advance the Precision Oncology Patient Identification Program in thyroid cancer. Through the program, Bayer will offer testing with Veracyte‚Aos Afirma Xpression Atlas (XA) to identify underlying genomic drivers, including NTRK gene fusions, within patients‚Ao tumors. The program will focus on patients with advanced or metastatic thyroid cancer that is radioactive iodine refractory (RAIR) who may potentially benefit ...
12/22/2020 Bayer and Veracyte Announce Precision Oncology Collaboration in Thyroid Cancer | Financial Buzz Bayer and Veracyte (Nasdaq: VCYT) today announced a new collaboration to advance the Precision Oncology Patient Identification Program in thyroid cancer. Through the program, Bayer will offer testing with Veracyte‚Aos Afirma Xpression Atlas (XA) to identify underlying genomic drivers, including NTRK gene fusions, within patients‚Ao tumors. The program will focus on patients with advanced or metastatic thyroid cancer that is radioactive iodine refractory (RAIR) who may potentially benefit ...
12/22/2020 Bayer and Veracyte Announce Precision Oncology Collaboration in Thyroid Cancer | Financial Buzz Bayer and Veracyte (Nasdaq:VCYT) today announced a new collaboration to advance the Precision Oncology Patient Identification Program in thyroid cancer. Through the program, Bayer will offer testing with Veracyte‚Aos Afirma Xpression Atlas (XA) to identify underlying genomic drivers, including NTRK gene fusions, within patients‚Ao tumors. The program will focus on patients with advanced or metastatic thyroid cancer that is radioactive iodine refractory (RAIR) who may potentially benefit ...
12/22/2020 Bayer and Veracyte ( Nasdaq:VCYT ) today announced a new collaboration to advance the Precision Oncology Patient Identification Program in thyroid cancer. Through the program, Bayer will offer testing with Veracyte‚Aos Afirma Xpression Atlas (XA) to identify underlying genomic drivers, including NTRK gene fusions, within patients‚Ao tumors. The program will focus on patients with advanced or metastatic thyroid cancer that is radioactive iodine refractory (RAIR) who may potentially benefit ...